At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 136 enrolled
Drug / intervention
Tizanidine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial
In Brief
A Phase 2 clinical trial evaluating Tizanidine, Placebo, and 1 other intervention for Spasticity. Completed, enrolled 136 participants across 1 site.
Detailed Summary
This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpasticity
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedApr 2013
Primary CompletionFeb 2014
Study CompletionMay 2014
TodayJul 2026
First PostedApr 24, 2013
Enrollment StartApr 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.2 years ago
Interventions
Tizanidinedrug
Placebodrug
Moxifloxacindrug